Memorial Sloan Kettering Cancer Center
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Inclusion Criteria: * Female patients ≥ 18 years of age * Histologic confirmation of Gynecologic Mesonephric or Mesonephric-like cancer (GMC). Patients with mixed histology are eligible if the disease is deemed by the treating physician to be driven by the GMC component. * Measurable disease according to RECIST 1.1 * Patients must have persistent (disease that is metastatic at presentation or remains present following first-line therapy) or recurrent disease (disease that has come back or progressed following prior surgery or treatment) * Patients with metastatic or recurrent disease do not r…
3.2 mg PO, twice weekly
200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.